Table 3– Clinical effectiveness outcomes at 6 and 12 months in patients having computed tomography (CT) suggestive of complete fissure, with endobronchial valve (EBV) therapy patients stratified by CT assessment of lobar occlusion
Complete fissure
Lobar occlusionNo lobar occlusionp-value#Controls
Patients n201719
Δ TLVR %+
 6 months-80±0.30-29±0.25<0.00010±0.08
 ≥55% reduction§15 (79)3 (18)0.00020 (0)
Δ TLC L
 6 months-0.5±0.7-0.4±1.00.7-0.2±0.5
 12 months-0.3±0.7-0.2±1.20.6-0.4±0.7
Δ FEV1 %
 6 months26±246±120.0043±14
 12 months28±322±100.005-2±22
 ≥15% improved12 (67)1 (8)0.0021 (6)
Δ cycle ergometry workload W
 6 months8±150±140.10-3±7
 12 months6±165±100.9-2±9
 ≥10 W improved8 (44)3 (27)0.41 (7)
Δ 6MWD %
 6 months22±38-2±190.0319±54
 12 months22±400±200.0610±44
 ≥35 m improved10 (56)3 (25)0.16 (38)
Δ SGRQ points
 6 months-10±15-2±140.23±15
 12 months-4±162±160.44±11
 ≥4 pts improved8 (67)4 (40)0.42 (17)
Δ RV/TLC %
 6 months-14±11-1±90.001-4±11
 12 months-14±110±130.003-2±10
Lost to follow-up2 (10)3 (18)0 (0)
Died0 (0)2 (12)1 (5)
  • Data are presented as mean±sd or n (%), unless otherwise stated. Δ: change; TLVR: target lobe volume reduction; TLC: total lung capacity; FEV1: forced expiratory volume in 1 s; 6MWD: 6-min walk distance; SGRQ: St George’s Respiratory Questionnaire; RV: residual volume. #: t-test comparison of the EBV-treated subgroup having lobar occlusion and the EBV-treated subgroup not having lobar occlusion (the control subgroup having CT suggestive of complete fissure is shown for reference); : lobar occlusion determination was not available for seven patients; +: TLVR based on CT collected at 6 months; §: 55% is presented as the threshold for TLVR since it was the median shown by EBV patients with CT suggestive of complete fissure.